A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit
MF Beal, D Oakes, I Shoulson, C Henchcliffe… - JAMA …, 2014 - jamanetwork.com
Importance Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function,
has been shown in preclinical Parkinson disease (PD) models to reduce the loss of
dopamine neurons, and was safe and well tolerated in early-phase human studies. A
previous phase II study suggested possible clinical benefit. Objective To examine whether
CoQ10 could slow disease progression in early PD. Design, Setting, and Participants A
phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American …
has been shown in preclinical Parkinson disease (PD) models to reduce the loss of
dopamine neurons, and was safe and well tolerated in early-phase human studies. A
previous phase II study suggested possible clinical benefit. Objective To examine whether
CoQ10 could slow disease progression in early PD. Design, Setting, and Participants A
phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American …